Crosslinked Hyaluronic Acid Gel for Uniform Triamcinolone Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing hyaluronic acid treatments for osteoarthritis have short-term efficacy due to rapid degradation and uneven dispersion of corticosteroids, leading to instability and reduced therapeutic effect.
Innovation Solution
A method involving crosslinking hyaluronic acid with 1,4-butanediol diglycidyl ether (BDDE) to form a gel that evenly disperses triamcinolone, eliminating the need for surfactants like polysorbate 80, ensuring sustained release and improved stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If linear hyaluronic acid is used, then it provides good biocompatibility and lubrication effect, but it is rapidly absorbed and degraded by the human body, resulting in short-term therapeutic effect
Solution Approach 1:
The patent changes the chemical structure parameter of hyaluronic acid from linear to crosslinked configuration. By introducing crosslinks between hyaluronic acid molecules, the degradation rate is reduced while maintaining biocompatibility, thereby extending the therapeutic effect duration to more than six months.
Solution Approach 2:
The patent creates a composite structure by crosslinking hyaluronic acid molecules with each other and with triamcinolone. This composite crosslinked network maintains the biocompatibility of hyaluronic acid while significantly reducing degradation rate, achieving both good biocompatibility and prolonged therapeutic effect.
2Duration of action of moving object
If crosslinked hyaluronic acid is used, then degradation time is prolonged and therapeutic effect lasts for more than six months, but manufacturing complexity increases due to additional crosslinking steps
Solution Approach 1:
The patent merges the crosslinking step with the formulation step. By adding the crosslinking agent to the hyaluronic acid and triamcinolone mixture during the formulation process and allowing crosslinking to occur in the final product, the manufacturing process is simplified compared to separate crosslinking steps, while still achieving prolonged therapeutic effect.
3Duration of action of moving object
If triamcinolone is dispersed in hyaluronic acid gel, then sustained-release effect is achieved, but uneven dispersion occurs leading to reduced therapeutic effect
Solution Approach 1:
The patent changes the physical state and concentration parameters of triamcinolone during formulation. By controlling the particle size, concentration, and mixing conditions, the patent achieves uniform dispersion of triamcinolone throughout the hyaluronic acid gel matrix, ensuring sustained-release effect without uneven distribution.
Solution Approach 2:
The patent performs preliminary mixing and dispersion of triamcinolone with hyaluronic acid before crosslinking. This preliminary action ensures uniform distribution of triamcinolone throughout the gel matrix before the crosslinking reaction locks in the structure, preventing uneven dispersion and ensuring consistent sustained-release performance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crosslinked hyaluronic acid gel provides a sustained-release effect for triamcinolone, enhancing therapeutic efficacy for osteoarthritis treatment by maintaining anti-inflammatory and analgesic effects for an extended period without surfactant-related instability.
Implementation Method 1
crosslinking the colloid of step (b) with 1,4-butanediol diglycidyl ether (BDDE)
Data Source
AI summary
The present disclosure provides a method for manufacturing a crosslinked hyaluronic acid gel and a crosslinked hyaluronic acid gel. The crosslinked hyaluronic acid gel contains substantially evenly distributed triamcinolone.